Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared on LinkedIn:
‘‘NovoNordisk has applied to the FDA for approval of Mim8, a bispecific antibody which will be a direct competitor to emicizumab (Hemlibra).
The data we have seen presented at scientific meetings and published are strong, and suggest that approval is likely to be given.”
Read the full article here.
Article: Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors
Stay updated on the emerging in the field of Hemophilia with Hemostasis Today.
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025
-
Mar 12, 2026, 16:36Giordano Botta: From the ‘Power of Zero’ to a Precise Understanding of Cardiovascular Risk
-
Mar 12, 2026, 16:31Katie Baca-Motes: Incorporating Menstrual Cycle and Hormonal Rhythms Into Clinical Research
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria